Generic Semaglutide 0.25

Generic Semaglutide 0.25 carries a boxed warning regarding the risk of thyroid C-cell tumors, including MTC. It is unknown if this medication causes thyroid C-cell tumors, including MTC, in humans. Other serious warnings include pancreatitis, gallbladder problems (cholelithiasis, cholecystitis), acute kidney injury, increased heart rate, and suicidal behavior and ideation. Inform your healthcare provider immediately if you experience any severe or unusual symptoms.

Generic Semaglutide 0.25 should not be used if you have a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with a prior serious hypersensitivity reaction to semaglutide or any components of the product. Do not use if you are pregnant or breastfeeding.

Common side effects may include nausea, vomiting, diarrhea, constipation, and abdominal pain. These side effects are often mild to moderate and tend to decrease over time as your body adjusts to the medication. Other common side effects can include headache, fatigue, and dyspepsia.

Generic Semaglutide 0.25 can slow gastric emptying, which may affect the absorption of orally administered medications. Caution should be exercised when co-administering oral medications, particularly those with a narrow therapeutic index. Inform your healthcare provider about all medications, supplements, and herbal products you are currently taking.

Always follow your healthcare provider's instructions for administering Generic Semaglutide 0.25. Do not share your injection pen with others, even if the needle is changed. Store the medication as directed. Seek immediate medical attention for symptoms of a severe allergic reaction, pancreatitis, or gallbladder issues. Regular follow-up with your healthcare provider is important to monitor your progress and manage any potential side effects.